

CLAIM AMENDMENTS

IN THE CLAIMS

This listing of the claims will replace all prior versions, and listing, of claims in the application or previous response to office action:

1. (Withdrawn) A cell deposition system comprising:
a hand held air-jet sprayer having a nozzle orifice with a pore size sufficient to allow passage of cells without damage; and
autologous cells,
the system operable to:
dispense the autologous cells using the air-jet sprayer onto an area of a subject lacking normal, healthy skin; and
grow three dimensional epithelial tissue on the area lacking normal, healthy skin.
2. (Withdrawn) The system of Claim 1, further comprising a dermal allograft material located in the area lacking normal, healthy skin.
3. (Withdrawn) The system of Claim 1, wherein the autologous cells further comprise keratinocytes.
4. (Withdrawn) The system of Claim 1, wherein the autologous cells further comprise fibroblasts.
5. (Withdrawn) The system of Claim 1, wherein the autologous cells further comprise stem cells.

6. (Withdrawn) The system of Claim 1, further comprising at least two types of autologous cells, the system further operable to dispense each type of autologous cell separately.

7. (Withdrawn) The system of Claim 1, further comprising the system operable to dispense at least one antibiotic, cytokine, adhesion factor, or growth factor.

8. (Withdrawn) The system of Claim 1, further comprising an air propellant used in the air-jet sprayer, the air selected from the group consisting of: carbon dioxide, water vapor, oxygen, nitrogen, argon, helium, neon, and any combination thereof.

9. (Withdrawn) The system of Claim 1, further comprising the nozzle having a pore size of approximately 1000 micrometers.

10. (Withdrawn) The system of Claim 1, further comprising the autologous cells suspended in a soluble medium in the air-jet sprayer, the soluble medium selected from the group consisting of: polyvinyl alcohol, albumin, dextrans, plasma, serum, other blood components, polymers of nucleic acids, and any combination thereof.

11. **(Currently Amended)** A method of dispersing living cells comprising:
forming a suspension consisting of a subject's **isolated** autologous stem cells and a soluble medium;

placing the suspension into a receptacle of an air-jet sprayer having a nozzle orifice with a pore size sufficient to allow passage of the suspension without damage to the autologous stem cells; and

dispersing the suspension onto an area of skin of the subject lacking normal, healthy skin using the **nozzle orifice of the** air-jet sprayer;

wherein the forming the suspension and dispersing steps occur after, but within hours of the initial formation of the area of skin lacking normal, healthy skin.

12. (Original) The method of Claim 11, further comprising placing a dermal allograft into the area lacking normal, healthy skin.

13. (Original) The method of Claim 11, further comprising dispersing the cells onto a tissue scaffold located in the area lacking normal, healthy skin.

14. (Previously Presented) The method of Claim 11, wherein the area lacking normal, healthy skin comprises a wound.

15. (Original) The method of Claim 11, further comprising growing a three dimensional epithelial tissue from the cells in the area lacking normal, healthy skin.

16-18. (Cancelled)

19. (Previously Presented) The method of Claim 11, further dispersing at least one other type of autologous cell suspension, separately onto the area lacking normal, healthy skin using the air-jet sprayer.

20. (Previously Presented) The method of Claim 11, further comprising dispensing at least one of antibiotic, cytokine, adhesion factor, or growth factor onto the area lacking normal, healthy skin using the air-jet sprayer.